Sesen Bio, Inc.

NasdaqCM:SESN Stok Raporu

Piyasa değeri: US$2.6b

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Sesen Bio Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

19.3%

Kazanç büyüme oranı

4.38%

EPS büyüme oranı

Biotechs kazanç büyümesi25.3%
Gelir büyüme oranı-85.7%
Gelecekteki özkaynak getirisin/a
Analist kapsamı

Low

Son güncelleme28 Feb 2023

Gelecekteki son büyüme güncellemeleri

Analiz Makalesi • Aug 12

Earnings Update: Here's Why Analysts Just Lifted Their Sesen Bio, Inc. (NASDAQ:SESN) Price Target To US$7.00

Investors in Sesen Bio, Inc. ( NASDAQ:SESN ) had a good week, as its shares rose 4.7% to close at US$4.04 following the...

Recent updates

Seeking Alpha • Sep 21

Sesen Bio and Carisma Therapeutics announce merger agreement

Sesen Bio (NASDAQ:SESN) and Carisma Therapeutics has entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on the advancement of Carisma’s proprietary cell therapy platform that utilizes engineered macrophages and monocytes to potentially transform the treatment of cancer and other serious disorders. The combined company expected to have ~$180M of cash, equivalents and marketable securities at close, including $30M from a concurrent financing by Carisma, which is expected to fund the combined company through 2024. Also, the cash runway of combined company expected to enable multiple clinical readouts across Carisma programs. The combined company is expected to operate under the name Carisma Therapeutics and trade on Nasdaq under the ticker symbol “CARM”.
Seeking Alpha • Aug 08

Sesen Bio GAAP EPS of -$0.16 misses by $0.03

Sesen Bio press release (NASDAQ:SESN): Q2 GAAP EPS of -$0.16 misses by $0.03. Company continues to assess potential strategic alternatives with the goal of maximizing shareholder value. Cash, cash equivalents and marketable securities were $161.2 million as of June 30, 2022, compared to $151.1 million as of June 30, 2021. Shares -1.82% PM.
Seeking Alpha • Jul 27

Sesen Bio granted additional time period for regaining compliance

Nasdaq Listing Qualifications department notified Sesen Bio (NASDAQ:SESN) that it has been granted a second 180-day grace period, or until Jan.23, 2023 for regaining compliance with the minimum bid price requirement. In January, the company had received its non-compliance letter and was granted time until July 25, 2022, to regain compliance with the minimum bid price requirement. The stock will be transferred to the Nasdaq Capital Market effective July 28, 2022 and will continue to trade under the current symbol. Shares trading 2% down premarket
Seeking Alpha • Jul 18

Sesen Bio slips after decision to pause U.S. studies for lead asset

The shares of cancer-focused biotech Sesen Bio (NASDAQ:SESN) traded lower in the pre-market Monday after the company announced its decision to pause further development of its lead asset Vicineum in the U.S. Sesen (SESN) noted that after discussions with the FDA, the company reassessed the development path for Vicineum, including a Phase 3 trial for the treatment in non-muscle invasive bladder cancer (NMIBC). The decision to pause further studies allows the company to save cash as it explores potential strategic alternatives to maximize shareholder value, according to the management. Additionally, Sesen (SESN) expects to form a partnership for the further development of Vicineum. However, the company’s Chief Executive, Dr. Thomas Cannell, noted that the current commercial environment of NMIBC also led to its decision. “We have also recently observed an evolution of the current treatment paradigm in NMIBC, with substantial uptake of intravesical chemotherapy (monotherapy and combination therapy) during the ongoing BCG shortage,” he said. In Aug. 2021, the FDA declined to approve Vicineum for the treatment of BCG-unresponsive NMIBC.
Seeking Alpha • Jun 02

Sesen Bio: Another Net-Net Biopharma Exploring Strategic Alternatives

SESN is a clinical-stage biopharma company working on the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). FDA declined to approve the company's flagship drug Vicineum. Subsequently, management has started a strategic review. SESN trades at $0.58/share vs $0.75/share of net cash.
Analiz Makalesi • Apr 17

We Think Sesen Bio (NASDAQ:SESN) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analiz Makalesi • Dec 05

We're Keeping An Eye On Sesen Bio's (NASDAQ:SESN) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Nov 24

Sesen Bio: Interesting Price Drop After CRL

Sesen received a CRL in August. Another trial will be needed. Sesen held a Type A meeting with the FDA on Oct. 29 on the CMC questions.
Seeking Alpha • Nov 17

Sesen Bio: Hoping For An Easy Revalidation Of Vicineum By 2022

The US FDA published the warning letter on October 27, 2021, just 2 days before CMC Type A meeting with Sesen Bio. The move informed its rejection of the BLA. Ahead of the Type A meeting, the burden of proof will be on Sesen’s side to show the efficacy of Vicineum post-2017. Sesen Bio is gearing towards product commercialization with strategic hires into 2022. Study shows that high-prescribing urologists would use a treatment agent branded with Vicineum in more than 80% of the BCG-unresponsive NMIBC patients as opposed to 17% with Keytruda. Sesen Bio is able to fund its capital operations including R&D until 2023 when it is expected to begin commercialization of Vicineum.
Seeking Alpha • Aug 23

Sesen Bio: The Road Ahead

The current FDA environment is under heavy scrutiny with much uncertainty. Sesen Bio's lead drug, Vicineum, received a complete response letter from the Agency which put tremendous pressure on the stock. The company is eager to conduct a Type A meeting with the FDA to discuss the path ahead.
Analiz Makalesi • Aug 12

Earnings Update: Here's Why Analysts Just Lifted Their Sesen Bio, Inc. (NASDAQ:SESN) Price Target To US$7.00

Investors in Sesen Bio, Inc. ( NASDAQ:SESN ) had a good week, as its shares rose 4.7% to close at US$4.04 following the...
Analiz Makalesi • Feb 18

News Flash: 3 Analysts Think Sesen Bio, Inc. (NASDAQ:SESN) Earnings Are Under Threat

Today is shaping up negative for Sesen Bio, Inc. ( NASDAQ:SESN ) shareholders, with the analysts delivering a...
Analiz Makalesi • Jan 26

Is Sesen Bio (NASDAQ:SESN) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. Indeed, Sesen Bio...
Analiz Makalesi • Dec 21

Sesen Bio, Inc.'s (NASDAQ:SESN) Profit Outlook

With the business potentially at an important milestone, we thought we'd take a closer look at Sesen Bio, Inc.'s...

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:SESN - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/2025N/A-9-18N/A1
12/31/2024N/A-8-8N/A1
12/31/2023N/A-26-20N/A1
12/31/202240-202525N/A
9/30/202260-31010N/A
6/30/20222048-29-29N/A
3/31/20222254-43-43N/A
12/31/2021270-69-69N/A
9/30/20217-24-65-65N/A
6/30/202118-118-54-54N/A
3/31/202116-119-40-40N/A
12/31/202011-23-31-31N/A
9/30/202011-41-36-36N/A
6/30/2020N/A-32-39-39N/A
3/31/2020N/A-60-39-38N/A
12/31/2019N/A-107-38-38N/A
9/30/2019N/A-81-32-31N/A
6/30/2019N/A-82-30-30N/A
3/31/2019N/A-36-26-26N/A
12/31/2018N/A-34-23-23N/A
9/30/2018N/A-33-19-19N/A
6/30/2018N/A-29-18-18N/A
3/31/2018N/A-27-17-17N/A
12/31/20170-29-18-18N/A
9/30/20171-26-20-20N/A
6/30/201730366N/A
3/31/201730366N/A
12/31/201630233N/A
9/30/201630-5N/A-1N/A
6/30/20161-34N/A-31N/A
3/31/20161-35N/A-35N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: SESN önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: SESN önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: SESN önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: SESN gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Yüksek Büyüme Geliri: SESN gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: SESN 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Büyüyen şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2023/03/08 06:35
Gün Sonu Hisse Fiyatı2023/03/07 00:00
Kazançlar2022/12/31
Yıllık Kazançlar2022/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Sesen Bio, Inc. 7 Bu analistlerden 1, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
John NewmanCanaccord Genuity
Swayampakula RamakanthH.C. Wainwright & Co.
Christopher HowertonJefferies LLC